- Details
- Michael Morris highlights notable prostate cancer trials, focusing on AMG 509, a bispecific antibody targeting STEAP1 and CD3. This promising early-phase study, still determining optimal dosages, shows potential in treating prostate cancer, a field historically resistant to immune therapy. Dr. Morris emphasizes AMG 509's ability to reduce bony and visceral diseases, including liver disease, with m...
|
- Details
- Pedro Barata engages in a conversation with Dan George about developments in kidney cancer treatments from the ESMO conference. Their discussion centers on the EVEREST trial, which investigates the use of the mTOR inhibitor everolimus in an adjuvant setting for high-risk kidney cancer patients post-nephrectomy. Dr. George emphasizes the significance of targeting high-risk patients, particularly th...
|
- Details
- Alicia Morgans interviews Christos Kyriakopoulos about a study presented at ESMO on EPI-7386, also known as masofaniten. Dr. Kyriakopoulos elaborates on this phase one-two study, which explores the combination of EPI-7386 with enzalutamide in patients with metastatic castration-resistant prostate cancer. EPI-7386 is novel in targeting the androgen receptor's N-terminal domain, differing from other...
|
- Details
- Ashish Kamat and Petros Grivas discuss recent advancements in metastatic bladder cancer treatments from ESMO Congress 2023. Key highlights include the CheckMate-901 and EV-302 trials. Dr. Grivas highlights the CheckMate-901 trial's success with the combination of gemcitabine, cisplatin, and nivolumab, which shows notable improvements in overall survival and progression-free survival with a managea...
|
- Details
- Alicia Morgans speaks with Cora Sternberg about the EV-302 study presented at ESMO 2023. This study marks a significant shift in treating advanced metastatic urothelial cancer, traditionally managed with cisplatin or carboplatin-based chemotherapy. EV-302 introduces a combination of enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, and pembrolizumab, an anti-PD-1 inhibitor im...
|
- Details
- Alan Bryce discusses the PSMAfore and other trials with Zach Klaassen. The trial, focusing on lutetium treatment for metastatic castration-resistant prostate cancer (mCRPC) in a pre-chemotherapy setting, shows a significant radiographic progression-free survival (rPFS) benefit. Dr. Bryce highlights the importance of selecting appropriate patients through PSMA PET scans prior to initiating treatmen...
|
- Details
- Neeraj Agarwal discusses the phase two LITESPARK-013 trial exploring the efficacy of belzutifan, a hypoxia-inducible transcription factor 2 alpha inhibitor, in treating metastatic renal cell carcinoma. The trial compares two doses of belzutifan (120 milligrams and 200 milligrams daily) in patients who have progressed on PD-1 axis inhibitors. The primary endpoint is the objective response rate, wit...
|
- Details
- Oliver Sartor welcomes Alicia Morgans to discuss the Phase III ARASTEP trial. Dr. Morgans explains that ARASTEP targets high-risk biochemical recurrence in hormone-sensitive patients, requiring a positive PSMA PET scan for enrollment. The trial compares the efficacy of ADT alone versus ADT with darolutamide, alongside SBRT to visible lesions, aiming to prolong metastasis-free survival (MFS). Uniqu...
|
- Details
- Oliver Sartor joins Alicia Morgans are discussing the eagerly anticipated results from the PSMAfore study (NCT04689828), a phase three trial exploring PSMA-617 lutetium for taxane-naive patients with metastatic castrate-resistant prostate cancer (mCRPC). Notable findings from the study revealed significantly improved radiographic progression-free survival (rPFS) with PSMA-617 lutetium vs a change...
|
- Details
- Medical Oncologists Alicia Morgans and Mark Markowski discuss challenges in treating advanced prostate cancer, related to the evolving resistance requiring novel mechanisms of action to give us new options for treatment. A new drug, masofaniten (formerly EPI-7386), is being studied in a phase II trial for metastatic castration-resistant prostate cancer (mCRPC). The trial aims to enroll 120 patient...
|
